Open AccessDiffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes
Author(s) -
Yan Xiao,
Miao Zhou,
Zhongze Lou,
Qitian Mu,
Lixia Sheng,
Ping Zhang,
Yichuan Wang,
Guifang Ouyang
Publication year - 2018
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.187285
Subject(s) - medicine , rituximab , hepatitis b virus , vincristine , diffuse large b cell lymphoma , regimen , prednisolone , cyclophosphamide , gastroenterology , chop , lymphoma , hepatitis b , oncology , immunology , chemotherapy , virus
Hepatitis B virus (HBV) infection is a risk factor in diffuse large B-cell lymphoma (DLBCL); however, little is known other than the prevalence evidence. In addition, the impact of HBV infection to DLBCL remains controversial. The purpose of this study was to investigate the HBV infection status of 136 patients with DLBCL, analyze the clinical property of HBV-infected patients, and determine the effects of HBV infection to the outcomes of DLBCL patients.